SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending due to intense speculation surrounding an imminent buyout and the anticipation of the 80th clinical trial event. Investors are actively discussing the potential impact of institutional accumulation and the company's oncology pipeline, leading to high-conviction sentiment and debates over its valuation and regulatory path.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is currently trending as a defensive anchor for investors amid a broader market rotation, with its strong portfolio of pharmaceutical and medical technology assets driving a push toward all-time highs. The community is actively discussing J&J's consistent dividend profile, potential acquisitions to strengthen its oncology pipeline, and the persistent legal overtones regarding talc litigation that continue to shape market sentiment.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently seeing heightened investor interest and increased trading volume as the market reacts to shifting narratives around its silicon-anode battery technology for emerging AI edge devices, drones, and smart glasses. The community remains deeply divided between long-term bulls encouraged by recent commercial scaling milestones and potential supply chain partnerships, and skeptics who remain focused on historical production delays and the pressure to prove execution at scale.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is generating significant investor interest following a major U.S. commercialization partnership with Tolmar and positive clinical trial progress across multiple oncology indications. The community is actively discussing the company's robust pipeline, significant de-risking milestones, and the disconnect between the stock's current price and its strong long-term growth potential.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors rally around the company's immunotherapy platform and pending global expansion, despite ongoing tension with a significant short interest. The community is actively discussing the potential of ANKTIVA and advanced NK cell manufacturing to disrupt oncology markets, with many hopeful that near-term regulatory and partnership catalysts will sustain the stock's current momentum.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is seeing high volatility as investors weigh a strong earnings beat and a new 4-for-1 stock split against concerns that its rapid growth and premium valuation are stretching expectations too far. The community is actively debating whether to treat the recent post-earnings pullback as a buying opportunity in a long-term cybersecurity leader or as a sign of deeper structural cooling in software valuations.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors react to the company's robust Q1 financial results and its continued aggressive oncology expansion, highlighted by the recent acquisition of Terns Pharmaceuticals. The community is actively discussing Merck's long-term pipeline strategy to address the looming patent cliff for Keytruda, while traders monitor the stock's technical chart patterns and M&A activity within the broader biopharma sector.

SharonAI Holdings, Inc. operates as a holding company that develops and delivers GPU cloud computing and AI solutions. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is currently experiencing intense market interest driven by a strategic pivot toward becoming a sovereign AI infrastructure provider, bolstered by a massive multi-year compute collaboration with NVIDIA. Community sentiment is heavily focused on the company's tight float, significant contracted pipeline in the APAC region, and strategic positioning as a neocloud play, with active discussion centered on whether this represents an early-stage institutional allocation or a momentum-driven squeeze.

WorldFinancial

WorldFinancial (WLFI) is facing intense community scrutiny and volatility as investors debate whether the token represents a genuine DeFi opportunity or a high-profile grift following reports of significant insider selling and legal disputes involving major stakeholders. While some retail investors remain bullish on potential supply shocks and upcoming governance vote catalysts, many are expressing frustration over the token's persistent downward trend and questioning the transparency of the project's management.

Ambiq Micro, Inc. engages in the provision of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI computing. It operates through the following geographical segments: China, Taiwan, Singapore, and Rest of the World. The company was founded by Scott Hanson, Dennis Sylvester, and David Blaauw on January 20, 2010 and is headquartered in Austin, TX.

Ambiq Micro Inc.

Ambiq Micro, Inc.

Ambiq Micro is gaining traction as a strategic play within the physical AI and robotics ecosystem, fueled by investor interest in its ultra-low-power edge AI chips. The community is actively tracking potential partnership rumors and institutional accumulation, with sentiment buoyed by the company's positioning as a foundational supplier for next-generation, battery-constrained devices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seres Therapeutics (NASDAQ:MCRB) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($2.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The company had revenue of $0.36 million during the...

Seres Therapeutics (MCRB) Projected to Post Quarterly Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 200 Day Moving Average   - Here's What Happened

Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell...

Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving Average - Here's What Happened

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50 Day Moving Average - Here's Why...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Down 15.4% in February

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) was the recipient of a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling...

Seres Therapeutics (NASDAQ:MCRB) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group restated a "buy" rating and issued a $22.00 price target on shares of Seres Therapeutics in a research report on Friday...

Seres Therapeutics (NASDAQ:MCRB) Issues Earnings Results

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported ($1.76) earnings per share for the quarter, beating analysts...

Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday

Seres Therapeutics (NASDAQ:MCRB) will be releasing its Status update earnings before the market opens on Thursday, March 12. (View Earnings Report at...

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average - What's Next?

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average - Should You Sell...

Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30%

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

MCRBSeres Therapeutics Inc

Fundamentals

Latest MCRB News